High expression of microRNA-199a-5p is associated with superior clinical outcomes in patients with locally advanced rectal cancer

2019 ◽  
Vol 146 (1) ◽  
pp. 105-115 ◽  
Author(s):  
Dong Won Baek ◽  
Gyeonghwa Kim ◽  
Byung Woog Kang ◽  
Hye Jin Kim ◽  
Su Yeon Park ◽  
...  
2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Felix Rühlmann ◽  
Indra Maria Windhof-Jaidhauser ◽  
Cornelius Menze ◽  
Tim Beißbarth ◽  
Hanibal Bohnenberger ◽  
...  

Abstract Background CREB-binding protein (CBP) and p300 represent histone acetyltransferases (HATs) and transcriptional coactivators that play essential roles in tumour initiation and progression. Both proteins are generally thought to function as tumour suppressors, although their distinct roles in colorectal cancer (CRC) remain inconsistent and ambiguous. Thus, we analysed the expression of these two HATs in human tissue samples from patients with locally advanced rectal cancer via immunohistochemistry and evaluated their potential impacts on future CRC diagnosis and treatment. Methods In our analysis, we included ninety-three (n = 93) patients diagnosed with adenocarcinoma in the upper third of the rectum. None of the patients received preoperative chemoradiotherapy, but the patients did undergo primary resection of the tumour within the phase II GAST-05 trial. By using H-scores, the expression of both proteins was visualised via immunohistochemistry in resected specimens from the patients. CBP and p300 expression were correlated with clinical and follow-up data. Results Our analysis showed that high expression of CBP was significantly associated with prolonged cancer-specific survival (CSS; p = 0.002). In univariate analysis, CBP was an independent prognostic parameter for CSS (p = 0.042). High nuclear CBP expression was observed in two-thirds of patients. In contrast, we could not find any significant correlation between the expression of p300 and cancer-specific survival in this cohort of patients (p = 0.09). We did not observe any cooperation between CBP and p300 in our analysis. Conclusions High expression of CBP was significantly associated with improved oncological outcomes. This finding could help to stratify patients in the future for CRC treatment. Histone deacetylase (HDAC) inhibitors are increasingly playing a role in oncological treatment and could additionally become therapeutic options in CRC. Our findings need to be further evaluated and verified in future clinical analyses.


2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e17756-e17756
Author(s):  
Gustavo Ferraris ◽  
Maria Fernanda Diaz Vazquez ◽  
Jorge Palazzo ◽  
Sharon Salenius ◽  
Steven E. Finkelstein ◽  
...  

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 81-81
Author(s):  
Rohit Kumar ◽  
Shruti Bhandari ◽  
Phuong Ngo ◽  
Sunny R K Singh ◽  
Sindhu Janarthanam Malapati ◽  
...  

81 Background: With cancer care changing at a rapid pace, patients are becoming increasingly involved with their management and oftentimes migrating to a different facility to seek better care. Our study evaluated the characteristics of such patients who were initially diagnosed at a community cancer center (CCC) and how this affects clinical outcomes. Methods: The National Cancer Database identified 11,977 patients with stage II/III rectal cancer initially diagnosed at a CCC between 2005 and 2015. Clinical characteristics and outcomes between patients who received all of their treatments at the CCC versus those who received part or all of their treatments elsewhere were compared using rank-sum and X2 tests where appropriate. Cox model was used for survival analysis. Results: Of the total population, 51% were stage II and 49% were stage III. Gender and ethnic distributions were similar between the groups. Approximately 44 % of patients received all their treatment at the CCC and 56% had part or all of their care elsewhere. Patients who migrated were younger (63 vs 65 years, p<0.001) and had govt insurance (43.5 vs 35.8%, p<0.001). On multivariate analysis, age <65 years (OR 1.12, 95% CI 1.02-1.24), govt insurance (OR 1.17, 95% CI 1.06-1.29), Charlson/Deyo comorbid score <2 (OR 1.29, 95% CI 1.11-1.49), higher income (OR 1.21, 95% CI 1.16-1.27) and Stage III (OR 1.15, 95% CI 1.07-1.24) were associated with higher probability of migration. The treatment characteristics and outcomes are shown in Table. The 5y-OS rate was better in patients who received part or all of their treatment at other institutions (adjusted HR 0.80, 95% CI 0.74-0.86, p<0.001). Conclusions: Further studies are needed to provide direction for future strategies to reduce the apparent survival disparities in patients who migrate from CCC. [Table: see text]


Chemotherapy ◽  
2017 ◽  
Vol 62 (5) ◽  
pp. 314-322 ◽  
Author(s):  
Ilaria Benevento ◽  
Francesca De Felice ◽  
Daniela Musio ◽  
Vincenzo Tombolini

Currently, neoadjuvant fluoropyrimidine-based chemoradiotherapy (CRT) is standard practice in the management of locally advanced rectal cancer (LARC). In the last decade there has been a lively interest in the improvement of clinical outcomes by modifying this standard regimen by the addition of further agents. We review combinations of targeted therapies and conventional CRT currently under investigation in LARC patients.


Sign in / Sign up

Export Citation Format

Share Document